Revenue rose 8.93% and net profit grew 11.38% year-over-year, driven by strong CNS drug sales and increased R&D investment. The company maintained high gross margins, expanded digital healthcare, and implemented a new stock incentive plan.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.